# BrainCells

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/braincells

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.braincellsinc.com
- Total disclosed funding: $68M
- Latest round: Series B (Apr 21, 2008)
- Investors on record: 9

## About

BrainCells is a technology company specializing in innovative solutions that enhance operational efficiency through advanced software applications for data analytics, project management, and customer relationship management.BrainCells is dedicated to developing technology solutions that improve operational efficiency. The company is headquartered in San Diego, US, and has undergone growth through strategic funding rounds, raising a total of USD 20.00 mn. Its most recent funding round was a VENTURE DEBT round of USD 1.97 mn on January 10, 2012. The company was founded by individuals whose prior entrepreneurial experience is noteworthy, although specific details are unmentioned.BrainCells specializes in delivering technology solutions aimed at enhancing operational efficiency across various sectors. Its core product offerings include a suite of software applications designed for data analytics, project management, and customer relationship management (CRM). These tools facilitate seamless collaboration among team members, streamline workflows, and provide actionable insights that drive decision-making. The company primarily serves mid-sized to large enterprises in industries such as finance, healthcare, and manufacturing, particularly in North America and Europe, focusing on improving supply chain visibility and optimizing customer engagement strategies.BrainCells generates revenue through a structured transaction model that includes subscription-based services and direct sales to consumers and businesses. Clients engage in annual subscriptions for access to comprehensive software features, benefiting from continuous updates and support. Additionally, BrainCells partners with resellers and integrators who offer its solutions as part of broader service packages. Flagship products include the AnalyticsPro and ProjectMaster applications, which significantly contribute to the company’s revenue stream. Pricing plans cater to various customer needs, reflecting the value and capabilities of these key products.BrainCells is actively working on the development of new products with the aim of enhancing its software capabilities. The company plans to expand its market reach into European regions by the end of 2013. The recent VENTURE DEBT funding of USD 1.97 mn will be allocated to support these initiatives, including product development and market expansion strategies.

## Funding rounds

- Series B, Apr 21, 2008, $20M — New Enterprise Associates, Oxford Bioscience Partners, Technology Partners, Pappas Capital, Alexandria Venture Investments, Bay City Capital, MedImmune Ventures, NeuroVentures
- Series B, Mar 10, 2008, $30M — Oxford Bioscience Partners, Technology Partners, Pappas Capital, Bay City Capital, MedImmune Ventures, NeuroVentures
- Series A, Jul 14, 2005, $18M — Oxford Bioscience Partners, Technology Partners, Pappas Capital, NeuroVentures, Bay Capital

## Investors

- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series A, Series B
- Technology Partners — Series A, Series B
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A, Series B
- NeuroVentures (https://capitalatlas.ai/funds/neuroventures) — Series A, Series B
- Bay Capital (https://capitalatlas.ai/funds/bay-capital) — Series A
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B